What difference does it make when an investor never has to sell? That question was at the heart of the final stage session on the first day of BioStock Life Science Summit 2026, where Flerie and Linc, two leading listed Swedish investment companies, compared their approaches to backing Nordic life science.
In a conversation moderated by Jan Erik Smith, Partner at GOBIA Enterprises, Flerie’s CFO Cecilia Stureborg von Schéele and Linc’s CEO Karl Tobieson described how they each select companies, build their portfolios and view active ownership, exits and valuations. Unlike venture funds, which must exit their holdings within the fund’s lifetime, both companies have no fixed investment horizon. Yet even with a longer horizon, exit opportunities are always at the back of an investor’s mind. The panel also offered an insider perspective on the current funding climate and the general state of Nordic life science.
Stureborg von Schéele has more than 20 years of experience in finance, including roles at Recipharm and KPMG, and worked on Viva Wine Group’s IPO. Tobieson has led Linc since 2020, after heading MedCap from 2008 to 2020, where he is now Chairman of the Board.
See the full panel discussion “Evergreen or Exit – The Investment Models Backing Nordic Life Science” below.
